Works matching AU ZHONG Lai-ping


Results: 44
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.

    Published in:
    Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-33080-8
    By:
    • Ju, Wu-tong;
    • Xia, Rong-hui;
    • Zhu, Dong-wang;
    • Dou, Sheng-jin;
    • Zhu, Guo-pei;
    • Dong, Min-jun;
    • Wang, Li-zhen;
    • Sun, Qi;
    • Zhao, Tong-chao;
    • Zhou, Zhi-hang;
    • Liang, Si-yuan;
    • Huang, Ying-ying;
    • Tang, Yong;
    • Wu, Si-cheng;
    • Xia, Jing;
    • Chen, Shi-qing;
    • Bai, Yue-zong;
    • Li, Jiang;
    • Zhu, Qi;
    • Zhong, Lai-ping
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome.

    Published in:
    Cancer Communications, 2021, v. 41, n. 3, p. 279, doi. 10.1002/cac2.12136
    By:
    • Ju, Wu‐tong;
    • Liu, Ying;
    • Wang, Li‐zhen;
    • Li, Jiang;
    • Ren, Guo‐xing;
    • Sun, Jian;
    • Tu, Wen‐yong;
    • Hu, Yong‐jie;
    • Ji, Tong;
    • Yang, Wen‐jun;
    • Li, Jun;
    • He, Yue;
    • Wang, Yan‐an;
    • Zhang, Chen‐ping;
    • Zhong, Lai‐ping;
    • Zhang, Zhi‐yuan
    Publication type:
    Article